Acadia Pharma Insider Kihara James Sells 11,421 Shares in Planned 10b5‑1 Move – Market Watches for Signals Ahead of EU Approval.
Insider sale at Acadia Pharmaceuticals shows routine portfolio rebalancing amid rising option activity and pending EU approval, giving investors a clear view of executive trading trends.
3 minutes to read






